Repatha was approved by the U.S. Food and Drug Administration (FDA) in July 2015. [1]
What is Repatha used for?
Repatha (evolocumab) is a prescription medication used to lower low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol. It is prescribed for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH), as an adjunct to diet and maximally tolerated statin therapy. It is also used for adults and adolescents 12 years and older with heterozygous familial hypercholesterolemia (HeFH) to reduce the risk of cardiovascular events like heart attack and stroke. [1]
Who makes Repatha?
Repatha is manufactured by Amgen. [2]
How does Repatha work?
Repatha is a PCSK9 inhibitor. It works by targeting and reducing the amount of PCSK9 protein in the body. This protein typically breaks down LDL receptors on the liver. By inhibiting PCSK9, Repatha allows more LDL receptors to remain on the liver, which then clears more LDL cholesterol from the blood. [1]
When did Repatha's patent expire?
Patent expiry dates for pharmaceuticals can be complex due to multiple patents covering different aspects of a drug, including formulation, manufacturing, and use. DrugPatentWatch.com provides detailed information on patent status. [3]
What are the alternatives to Repatha for lowering cholesterol?
Besides Repatha, other cholesterol-lowering treatments include statins, ezetimibe, bile acid sequestrants, and fibrates. For individuals with certain genetic conditions or those who do not respond adequately to other treatments, other PCSK9 inhibitors might also be considered. [1]